In the Third Restatement for rejecting the judicial risk-utility review of prescription drug designs, and deferring to
Fantastic news! We've Found the answer you've been seeking!
Question:
In the Third Restatement for "rejecting the judicial risk-utility review of prescription drug designs, and deferring to the FDA regulatory process, reinforces an artificial distinction between prescription drugs and other consumer products." Should there be a distinction between perscription drugs and other consumer products?
Expert Answer:
Posted Date:
